Cefprozil for Oral Suspension USP — Class II drug recall D-0332-2021
Terminated recall by Lupin Pharmaceuticals Inc., reported 2021-04-21, distributed nationwide. Superpotent Drug
| Recall number | D-0332-2021 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2021-03-26 |
| Classified | 2021-04-12 |
| Reported by FDA | 2021-04-21 |
| Terminated | 2021-12-16 |
| Distributed | Nationwide (US) |
| Reason classes | potency |
| NDC | 68180-0401, 68180-0401-01, 68180-0401-02, 68180-0401-03, 68180-0402, 68180-0402-01, 68180-0402-02, 68180-0402-03 |
| Expiration dates | 2021-06-20 |
Product
Cefprozil for Oral Suspension USP, 250mg/5mL, packaged as a) 50 mL (when mixed) bottles (NDC 68180-402-01); b) 75 mL (when mixed) bottles (NDC 68180-402-02); and c) 100 mL (when mixed) bottles (NDC 68180-402-03); Rx only, Manufactured for: Lupin Pharmaceutical, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Mandideep 462 046, India.
Reason for recall
Superpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0332-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.